Ongoing Phase III Study Could Provide Xinlay Back-Up Option, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA reject the current application, which uses a meta-analysis of subgroups from two failed trials
You may also be interested in...
Abbott Receives Xinlay “Not Approvable” Letter
Letter follows a unanimous recommendation by FDA’s Oncologic Drugs Advisory Committee against approving atrasentan for treatment of hormone refractory prostate cancer in patients with disease metastatic to bone.
Abbott Receives Xinlay “Not Approvable” Letter
Letter follows a unanimous recommendation by FDA’s Oncologic Drugs Advisory Committee against approving atrasentan for treatment of hormone refractory prostate cancer in patients with disease metastatic to bone.
Abbott Xinlay Not Ready For Approval Or Abandonment, Committee Says
FDA's Oncologic Drugs Advisory Committee unanimously recommends against approval of Abbott's prostate cancer therapy atrasentan.